Biodesix, Inc. Earnings Recaps
Q3 2025
Nov 4, 2025
Biodesix reported strong third-quarter results for 2025, achieving a 20% increase in revenue and improved gross margins, while laying the groundwork for future growth in personalized diagnostics.
Key takeaways
- Revenue growth accelerated to 20% year-over-year, indicating robust demand for diagnostic tests.
- Gross margins improved by 400 basis points to 81%, reflecting operational effectiveness.
- Adjusted EBITDA enhanced by 18%, signaling progress towards profitability in Q4.
- Tests ordered from primary care surged 75% YOY, as the company expands its market strategy to enhance lung cancer diagnostics.
- Average revenue per test increased by 7% from Q2, supported by successful market access initiatives.